Co Meloxicam · DIN 02250012 · 7.5 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 2021 · checked November 19, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Co Meloxicam · DIN 02250012
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2004-09-14
Health Canada: Cancelled post market since 2021-07-30 · brand ACT MELOXICAM · ATC M01AC06 MELOXICAM · form Tablet · route Oral · ingredients MELOXICAM 7.5 MG · company Teva canada limited · schedule Prescription
Co Meloxicam: Formulary list price $0.20 per unit (the source does not state the unit; exact figure $0.2003). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02250012)
Source record
DIN 02250012: Co Meloxicam
Raw flags: sec3=Y
Item: 280804083; group id 387; item number 0925; lccId None; manufacturer id COB
Source form: Tab; strength: 7.5mg
Recorded listing: General benefit
Source prices (unrounded): $0.2003; ministry $0.2003
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02250012
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73483
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Meloxicam · DIN 02248973 · $0.2003
Auro-Meloxicam · DIN 02390884 · $0.2003
Meloxicam · DIN 02353148 · $0.2003
Mobicox · DIN 02242785 · not recorded
PMS-Meloxicam · DIN 02248267 · $0.2003
Teva-Meloxicam · DIN 02258315 · $0.2003
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since July 30, 2021 — choose a marketed DIN from the same-category list.